Mydrane

Lidocaine Hydrochloride Monohydrate, the active ingredient in Mydrane, is a local anesthetic presented as a sterile intracameral solution for intra‑ocular use. Combined with phenylephrine hydrochloride and tropicamide, the formulation delivers rapid pupil dilation and corneal anesthesia for cataract extraction and other anterior segment surgeries.

GNH USA supplies Mydrane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, ophthalmic surgical centres and clinics worldwide, adhering to EU quality standards and providing full regulatory documentation for global distribution, with reliable logistics and cold‑chain support where required.

Mydrane is employed in ophthalmic procedures to achieve mydriasis and local anesthesia of the anterior segment. - Cataract surgery: provides rapid pupil dilation and intra‑ocular anesthesia to facilitate lens removal. - Intra‑ocular lens implantation: ensures adequate pupil size for precise lens positioning. - Anterior segment procedures (e.g., trabeculectomy, iridectomy): supplies anesthesia and dilation of the iris for safe surgical access.

Mydrane may cause ocular and systemic reactions; reported events are categorized by frequency.

Common Side Effects: - Transient ocular pain: mild discomfort lasting minutes after injection. - Conjunctival hyperemia: temporary redness of the eye. - Blurred vision: short‑term visual disturbance that resolves as the drug wears off. - Mild increase in intra‑ocular pressure: usually self‑limiting.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis or angioedema requiring immediate medical attention. - Persistent mydriasis: prolonged pupil dilation that may impair vision. - Retinal toxicity or endophthalmitis: rare but sight‑threatening intra‑ocular infections.

When using Mydrane, clinicians should observe the following precautions to minimize risk. - Assess allergy: confirm no known hypersensitivity to lidocaine, phenylephrine or tropicamide. - Monitor intra‑ocular pressure: watch for spikes after injection, especially in glaucoma patients. - Use caution in cardiovascular disease: phenylephrine may cause systemic vasoconstriction and hypertension. - Avoid in narrow‑angle glaucoma: excessive dilation can precipitate angle‑closure attacks. - Pregnancy and lactation: safety not established; use only if benefit outweighs potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mydrane can interact with other medications; relevant interactions are grouped by clinical significance.

Major Interactions (Avoid): - Systemic alpha‑adrenergic agonists (e.g., norepinephrine): may cause excessive hypertension. - Other ocular vasoconstrictors (e.g., epinephrine): additive pressor effects increase cardiovascular risk. - Concurrent use of additional local anesthetics: raises risk of cumulative lidocaine toxicity.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: phenylephrine may diminish blood‑pressure control, requiring monitoring. - Anticholinergic agents: may enhance the mydriatic effect of tropicamide, leading to prolonged dilation.